EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome
Portfolio Pulse from Vandana Singh
NeurAxis Inc (NYSE:NRXS) announced the publication of a study evaluating the efficacy of its IB-Stim technology in treating functional abdominal pain disorders (FAPDs) in adolescents. The study showed significant improvements in patients' quality of life and reductions in abdominal pain, nausea, disability, and anxiety. Despite the positive news, NRXS shares are down 21.1% at $4.10 premarket.
September 12, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Despite the positive results from the study of NeurAxis' IB-Stim technology, the company's shares are down 21.1% premarket.
The study results show that NeurAxis' IB-Stim technology is effective in treating FAPDs in adolescents, which could potentially increase the company's market share in the health tech industry. However, despite the positive news, the company's shares are down 21.1% premarket, indicating a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100